Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Retatrutides triple-receptor approach (GLP-1 + GIP + glucagon) delivered 28.7% weight loss in Phase 3 and addresses energy expenditure in ways that neither Semaglutide, Cagrilintide, or even Tirzepatide can touch
Net contents: 90 Tablets
The same vial with 2mL water is 5mg/mL
About the author: The landscape of weight loss and metabolic health optimization is evolving rapidly, and one of the most significant developments has been the widespread adoption of GLP-1 medications like Ozempic and Wegovy
Survodutide is a candidate drug in the obesity treatment pipeline, belonging to a class of dual GLP-1 and GCGR agonists
Akkermansia muciniphila 167 million AFU +
US$ 20.02
US$ 26.16
US$ 27.86
US$ 24.61
US$ 29.89
